Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karl Nocka is active.

Publication


Featured researches published by Karl Nocka.


Journal of Immunology | 2006

Cutting Edge: Interleukin 4-Dependent Mast Cell Proliferation Requires Autocrine/Intracrine Cysteinyl Leukotriene-Induced Signaling

Yongfeng Jiang; Yoshihide Kanaoka; Chunl Feng; Karl Nocka; Sudhir Rao; Joshua A. Boyce

Reactive mastocytosis (RM) in epithelial surfaces is a consistent Th2-associated feature of allergic disease. RM fails to develop in mice lacking leukotriene (LT) C4 synthase (LTC4S), which is required for cysteinyl leukotriene (cys-LT) production. We now report that IL-4, which induces LTC4S expression by mast cells (MCs), requires cys-LTs, the cys-LT type 1 receptor (CysLT1), and Gi proteins to promote MC proliferation. LTD4 (10–1000 nM) enhanced proliferation of human MCs in a CysLT1-dependent, pertussis toxin-sensitive manner. LTD4-induced phosphorylation of ERK required transactivation of c-kit. IL-4-driven comitogenesis was likewise sensitive to pertussis toxin or a CysLT1-selective antagonist and was attenuated by treatment with leukotriene synthesis inhibitors. Mouse MCs lacking LTC4S or CysLT1 showed substantially diminished IL-4-induced comitogenesis. Thus, IL-4 induces proliferation in part by inducing LTC4S and cys-LT generation, which causes CysLT1 to transactivate c-kit in RM.


Journal of Immunology | 2009

Mast Cell-Dependent Contraction of Human Airway Smooth Muscle Cell-Containing Collagen Gels: Influence of Cytokines, Matrix Metalloproteases, and Serine Proteases

Alexander Margulis; Karl Nocka; Agnes Brennan; Bijia Deng; Margaret Fleming; Samuel J. Goldman; Marion T. Kasaian

In asthma, mast cells infiltrate the airway smooth muscle cell layer and secrete proinflammatory and profibrotic agents that contribute to airway remodeling. To study the effects of mast cell activation on smooth muscle cell-dependent matrix contraction, we developed coculture systems of human airway smooth muscle cells (HASM) with primary human mast cells derived from circulating progenitors or with the HMC-1 human mast cell line. Activation of primary human mast cells by IgE receptor cross-linking or activation of HMC-1 cells with C5a stimulated contraction of HASM-embedded collagen gels. Contractile activity could be transferred with conditioned medium from activated mast cells, implicating involvement of soluble factors. Cytokines and proteases are among the agents released by activated mast cells that may promote a contractile response. Both IL-13 and IL-6 enhanced contraction in this model and the activity of IL-13 was ablated under conditions leading to expression of the inhibitory receptor IL-13Rα2 on HASM. In addition to cytokines, matrix metalloproteinases (MMPs), and serine proteases induced matrix contraction. Inhibitor studies suggested that, although IL-13 could contribute to contraction driven by mast cell activation, MMPs were critical mediators of the response. Both MMP-1 and MMP-2 were strongly expressed in this system. Serine proteases also contributed to contraction induced by mast cell-activating agents and IL-13, most likely by mediating the proteolytic activation of MMPs. Hypercontractility is a hallmark of smooth muscle cells in the asthmatic lung. Our findings define novel mechanisms whereby mast cells may modulate HASM-driven contractile responses.


Journal of Immunology | 2008

RGS13 Controls G Protein-Coupled Receptor-Evoked Responses of Human Mast Cells

Geetanjali Bansal; Jeffrey A. DiVietro; Hye Sun Kuehn; Sudhir Rao; Karl Nocka; Alasdair M. Gilfillan; Kirk M. Druey

IgE-mediated mast cell degranulation and release of vasoactive mediators induced by allergens elicits allergic responses. Although G protein-coupled receptor (GPCR)-induced signals may amplify IgE-dependent degranulation, how GPCR signaling in mast cells is regulated remains incompletely defined. We investigated the role of regulator of G protein signaling (RGS) proteins in the modulation of these pathways in human mast cells. Several RGS proteins were expressed in mast cells including RGS13, which we previously showed inhibited IgE-mediated mast cell degranulation and anaphylaxis in mice. To characterize how RGS13 affects GPCR-mediated functions of human mast cells, we analyzed human mast cell lines (HMC-1 and LAD2) depleted of RGS13 by specific small interfering RNA or short hairpin RNA and HMC-1 cells overexpressing RGS13. Transient RGS13 knockdown in LAD2 cells lead to increased degranulation to sphingosine-1-phosphate but not to IgE-Ag or C3a. Relative to control cells, HMC-1 cells stably expressing RGS13-targeted short hairpin RNA had greater Ca2+ mobilization in response to several natural GPCR ligands such as adenosine, C5a, sphingosine-1-phosphate, and CXCL12 than wild-type cells. Akt phosphorylation, chemotaxis, and cytokine (IL-8) secretion induced by CXCL12 were also greater in short hairpin RGS13-HMC-1 cells compared with control. RGS13 overexpression inhibited CXCL12-evoked Ca2+ mobilization, Akt phosphorylation and chemotaxis. These results suggest that RGS13 restricts certain GPCR-mediated biological responses of human mast cells.


Proceedings of the National Academy of Sciences of the United States of America | 2004

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Berkley Lynch; Nathalie Lambeng; Karl Nocka; Patricia Kensel-Hammes; Sandra M. Bajjalieh; Alain Matagne; Bruno Fuks


Nature Immunology | 2008

Suppression of immunoglobulin E-mediated allergic responses by regulator of G protein signaling 13.

Geetanjali Bansal; Zhihui Xie; Sudhir Rao; Karl Nocka; Kirk M. Druey


Archive | 2003

Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases

Berkley Lynch; Karl Nocka; Bruno Fuks


Archive | 2003

Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)

Berkley Lynch; Karl Nocka; Bruno Fuks


Archive | 2006

Mast cell activation using siglec 6 antibodies

Karl Nocka; Sudhir Rao


The Journal of Allergy and Clinical Immunology | 2004

Modulation of signaling proteins in cultured mast cells from chronic idiopathic urticaria patients

Becky M. Vonakis; Karl Nocka; Sudhir Rao; S. Gibbons; K. Vasagar; Sarbjit S. Saini


Archive | 2015

proliferation of human airway smooth muscle cells Tryptase and agonists of PAR-2 induce the

Andrew F. Walls; Jennifer A. Cairns; Alan R. McEuen; Roger Marthan; Diahn-Warng Perng; Hiran Thabrew; Steven J. Compton; J. Goldman; Marion T. Kasaian; Alexander Margulis; Karl Nocka; Agnes Brennan; Bijia Deng; Margaret Fleming; Imane Bara; A. Ozier; P. Berger; S. Zuyderduyn

Collaboration


Dive into the Karl Nocka's collaboration.

Top Co-Authors

Avatar

Geetanjali Bansal

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kirk M. Druey

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge